| Citation: |
LI Zhiyong, WANG Jing, ZHOU Yali, YUAN Dong. Research Progress in Blood Pressure Management after Aortic Dissection[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(4): 904-910. DOI: 10.12290/xhyxzz.2023-0643
|
Hypertension (HT) can induce aortic dissection (AD) by increasing the tension of the aortic wall and promoting tissue degradation, and continuous HT may increase the risk of aortic-related death. It is a significant factor in poor prognosis for AD and the most important controllable factor. Research has shown that blood pressure management after AD can reduce the incidence rate and mortality of AD, so controlling HT is an important goal and means of AD treatment. This article reviews the research progress on the impact of AD on blood pressure, the significance and methods of blood pressure management after AD, with the hope of providing reference for the treatment of AD patients and benefiting them.
| [1] |
Whelton P K, Carey R M, Aronow W S, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines[J]. Hypertension, 2018, 71(6): e13-e115.
|
| [2] |
Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people[J]. Lancet, 2014, 383(9932): 1899-1911. DOI: 10.1016/S0140-6736(14)60685-1
|
| [3] |
Eggebrecht H, Schmermund A, von Birgelen C, et al. Resistant hypertension in patients with chronic aortic dissection[J]. J Hum Hypertens, 2005, 19(3): 227-231. DOI: 10.1038/sj.jhh.1001800
|
| [4] |
Bossone E, Eagle K A. Epidemiology and management of aortic disease: aortic aneurysms and acute aortic syndromes[J]. Nat Rev Cardiol, 2021, 18(5): 331-348. DOI: 10.1038/s41569-020-00472-6
|
| [5] |
Thomas N. Hypertensive management[J]. Crit Care Nurs Clin North Am, 2023, 35(1): 31-38. DOI: 10.1016/j.cnc.2022.11.001
|
| [6] |
Nienaber C A, Yuan X. Taming hypertension to prevent aortic dissection: universal recognition of a "new normal" blood pressure?[J]. Circulation, 2022, 145(9): 645-647. DOI: 10.1161/CIRCULATIONAHA.121.058133
|
| [7] |
Evangelista A, Isselbacher E M, Bossone E, et al. Insights from the international registry of acute aortic dissection: a 20-year experience of collaborative clinical research[J]. Circulation, 2018, 137(17): 1846-1860. DOI: 10.1161/CIRCULATIONAHA.117.031264
|
| [8] |
Shalaeva E V, Messerli F H. What is resistant arterial hypertension?[J]. Blood Press, 2023, 32(1): 2185457. DOI: 10.1080/08037051.2023.2185457
|
| [9] |
Patel K V, Li X L, Kondamudi N, et al. Prevalence of apparent treatment-resistant hypertension in the United States according to the 2017 high blood pressure guideline[J]. Mayo Clin Proc, 2019, 94(5): 776-782. DOI: 10.1016/j.mayocp.2018.12.033
|
| [10] |
Januzzi J L, Sabatine M S, Choi J C, et al. Refractory systemic hypertension following type B aortic dissection[J]. Am J Cardiol, 2001, 88(6): 686-688. DOI: 10.1016/S0002-9149(01)01818-5
|
| [11] |
Koracevic G, Lovic D, Zdravkovic M, et al. Long-lasting, resistant hypertension should be a part of the aortic dissection risk score[J]. Hypertens Res, 2019, 42(11): 1836-1838. DOI: 10.1038/s41440-019-0305-8
|
| [12] |
Erbel R, Aboyans V, Boileau C, et al. 2014 ESC guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2014, 35(41): 2873-2926. DOI: 10.1093/eurheartj/ehu281
|
| [13] |
Li A, Mohetaer D, Zhao Q, et al. The relationship between renal artery involvement in Stanford B-type aortic dissection and the short-term prognosis: a single-centre retrospective cohort study[J]. Heart Lung Circ, 2019, 28(8): 1261-1266. DOI: 10.1016/j.hlc.2018.07.002
|
| [14] |
Ge Y P, Li C N, Li Y, et al. Relationship between renal function and renal artery involvement in acute Debakey type I aortic dissection[J]. Heart Surg Forum, 2020, 23(4): E465-E469. DOI: 10.1532/hsf.3023
|
| [15] |
van Bakel P A J, Henry M, Kim K M, et al. Imaging features of renal malperfusion in aortic dissection[J]. Eur J Cardiothorac Surg, 2022, 61(4): 805-813. DOI: 10.1093/ejcts/ezab555
|
| [16] |
Lin Y J, Chen Y P, Peng Y C, et al. Symptoms of post-traumatic stress disorder and associated risk factors in type A aortic dissection[J]. J Cardiovasc Surg (Torino), 2021, 62(3): 286-293.
|
| [17] |
Blakeslee-Carter J, Menon A J, Novak Z, et al. Association of mental health disorders and aortic dissection[J]. Ann Vasc Surg, 2021, 77: 217-225. DOI: 10.1016/j.avsg.2021.05.054
|
| [18] |
Camafort M, Ihm S H, Ruilope L M. Renal denervation for the treatment of hypertension and kidney disease[J]. Curr Opin Nephrol Hypertens, 2023, 32(6): 544-550. DOI: 10.1097/MNH.0000000000000928
|
| [19] |
Tseilikman V, Komelkova M, Kondashevskaya M V, et al. A rat model of post-traumatic stress syndrome causes phenotype-associated morphological changes and hypofunction of the adrenal gland[J]. Int J Mol Sci, 2021, 22(24): 13235. DOI: 10.3390/ijms222413235
|
| [20] |
Reed A B, Faizer R, James Valentine R. The impact of pre-existing blood pressure control in patients with acute aortic dissections[J]. Vascular, 2022, 30(6): 1051-1057. DOI: 10.1177/17085381211042152
|
| [21] |
Otaki Y, Watanabe T, Konta T, et al. Effect of hypertension on aortic artery disease-related mortality-3.8-year nationwide community-based prospective cohort study[J]. Circ J, 2018, 82(11): 2776-2782. DOI: 10.1253/circj.CJ-18-0721
|
| [22] |
Kimura N, Aizawa K, Kawahito K, et al. Outcomes of early-onset acute type a aortic dissection-influence of etiologic factors[J]. Circ J, 2019, 83(2): 285-294. DOI: 10.1253/circj.CJ-18-0969
|
| [23] |
Gawinecka J, Schönrath F, Von Eckardstein A. Acute aortic dissection: pathogenesis, risk factors and diagnosis[J]. Swiss Med Wkly, 2017, 147: w14489.
|
| [24] |
Song C, Yu G Y, Feng X, et al. Impact of high blood pressure variability on the occurrence of acute type B aortic dissection[J]. Vascular, 2020, 28(4): 413-420. DOI: 10.1177/1708538120902630
|
| [25] |
Zhang L, Tian W, Feng R, et al. Prognostic impact of blood pressure variability on aortic dissection patients after endovascular therapy[J]. Medicine (Baltimore), 2015, 94(38): e1591. DOI: 10.1097/MD.0000000000001591
|
| [26] |
Schutte A E, Kollias A, Stergiou G S. Blood pressure and its variability: classic and novel measurement techniques[J]. Nat Rev Cardiol, 2022, 19(10): 643-654. DOI: 10.1038/s41569-022-00690-0
|
| [27] |
Jana S, Hu M, Shen M C, et al. Extracellular matrix, regional heterogeneity of the aorta, and aortic aneurysm[J]. Exp Mol Med, 2019, 51(12): 1-15.
|
| [28] |
Lewis C E, Fine L J, Beddhu S, et al. Final report of a trial of intensive versus standard blood-pressure control[J]. N Engl J Med, 2021, 384(20): 1921-1930. DOI: 10.1056/NEJMoa1901281
|
| [29] |
Ribeiro F, Teixeira M, Alves A J, et al. Lifestyle medicine as a treatment for resistant hypertension[J]. Curr Hypertens Rep, 2023, 25(10): 313-328. DOI: 10.1007/s11906-023-01253-5
|
| [30] |
Carey R M, Muntner P, Bosworth H B, et al. Prevention and control of hypertension: JACC health promotion series[J]. J Am Coll Cardiol, 2018, 72(11): 1278-1293. DOI: 10.1016/j.jacc.2018.07.008
|
| [31] |
Xie H J, Li J C, Zhu X M, et al. Association between healthy lifestyle and the occurrence of cardiometabolic multimorbidity in hypertensive patients: a prospective cohort study of UK Biobank[J]. Cardiovasc Diabetol, 2022, 21(1): 199. DOI: 10.1186/s12933-022-01632-3
|
| [32] |
Blumenthal J A, Hinderliter A L, Smith P J, et al. Effects of lifestyle modification on patients with resistant hypertension: results of the TRIUMPH randomized clinical trial[J]. Circulation, 2021, 144(15): 1212-1226. DOI: 10.1161/CIRCULATIONAHA.121.055329
|
| [33] |
Flynn J T, Kaelber D C, Baker-Smith C M, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents[J]. Pediatrics, 2017, 140(3): e20171904. DOI: 10.1542/peds.2017-1904
|
| [34] |
Yeghiazarians Y, Jneid H, Tietjens J R, et al. Obstructive sleep apnea and cardiovascular disease: a scientific statement from the American Heart Association[J]. Circulation, 2021, 144(3): e56-e67.
|
| [35] |
Perger E, Pengo M F, Lombardi C. Hypertension and atrial fibrillation in obstructive sleep apnea: Is it a menopause issue?[J]. Maturitas, 2019, 124: 32-34. DOI: 10.1016/j.maturitas.2019.02.012
|
| [36] |
Akashiba T, Inoue Y, Uchimura N, et al. Sleep apnea syndrome (SAS) clinical practice guidelines 2020[J]. Respir Investig, 2022, 60(1): 3-32. DOI: 10.1016/j.resinv.2021.08.010
|
| [37] |
Iida H, Kurita N, Takahashi S, et al. Salt intake and body weight correlate with higher blood pressure in the very elderly population: the Sukagawa study[J]. J Clin Hypertens (Greenwich), 2019, 21(7): 942-949. DOI: 10.1111/jch.13593
|
| [38] |
Huggins C E, Margerison C, Worsley A, et al. Influence of dietary modifications on the blood pressure response to antihypertensive medication[J]. Br J Nutr, 2011, 105(2): 248-255. DOI: 10.1017/S0007114510003223
|
| [39] |
Akhlaghi M. Dietary approaches to stop hypertension (DASH): potential mechanisms of action against risk factors of the metabolic syndrome[J]. Nutr Res Rev, 2020, 33(1): 1-18. DOI: 10.1017/S0954422419000155
|
| [40] |
Middlekauff H R, Cooper Z D, Strauss S B. Drugs of misuse: focus on vascular dysfunction[J]. Can J Cardiol, 2022, 38(9): 1364-1377. DOI: 10.1016/j.cjca.2022.04.011
|
| [41] |
Isselbacher E M, Preventza O, Hamilton Black J 3rd, et al. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: a report of the American Heart Association/American College of Cardiology Joint Committee on clinical practice guidelines[J]. Circulation, 2022, 146(24): e334-e482.
|
| [42] |
Chaddha A, Erickson S, Kline-Rogers E, et al. Medication adherence patterns in aortic dissection survivors[J]. Indian J Med Res, 2018, 147(2): 183-188. DOI: 10.4103/ijmr.IJMR_1198_15
|
| [43] |
Ishiyama Y, Hoshide S, Mizuno H, et al. Constipation-induced pressor effects as triggers for cardiovascular events[J]. J Clin Hypertens (Greenwich), 2019, 21(3): 421-425. DOI: 10.1111/jch.13489
|
| [44] |
Tehrani A Y, White Z, Milad N, et al. Blood pressure-independent inhibition of Marfan aortic root widening by the angiotensin Ⅱ receptor blocker valsartan[J]. Physiol Rep, 2021, 9(10): e14877.
|
| [45] |
Hofmann Bowman M A, Eagle K A, Milewicz D M. Update on clinical trials of losartan with and without β-Blockers to block aneurysm growth in patients with Marfan syndrome: a review[J]. JAMA Cardiol, 2019, 4(7): 702-707. DOI: 10.1001/jamacardio.2019.1176
|
| [46] |
Strauss M H, Hall A S, Narkiewicz K. The combination of beta-blockers and ACE inhibitors across the spectrum of cardiovascular diseases[J]. Cardiovasc Drugs Ther, 2023, 37(4): 757-770. DOI: 10.1007/s10557-021-07248-1
|
| [47] |
Gao Q N, Xu L, Cai J. New drug targets for hypertension: a literature review[J]. Biochim Biophys Acta Mol Basis Dis, 2021, 1867(3): 166037. DOI: 10.1016/j.bbadis.2020.166037
|
| [48] |
Filippone E J, Naccarelli G V, Foy A J. Controversies in hypertension V: resistant and refractory hypertension[J]. Am J Med, 2024, 137(1): 12-22. DOI: 10.1016/j.amjmed.2023.09.015
|
| [49] |
Peacock E, Krousel-Wood M. Adherence to antihypertensive therapy[J]. Med Clin North Am, 2017, 101(1): 229-245. DOI: 10.1016/j.mcna.2016.08.005
|
| [50] |
Tajeu G S, Kent S T, Kronish I M, et al. Trends in antihypertensive medication discontinuation and low adherence among Medicare beneficiaries initiating treatment from 2007 to 2012[J]. Hypertension, 2016, 68(3): 565-575. DOI: 10.1161/HYPERTENSIONAHA.116.07720
|
| [51] |
Gwadry-Sridhar F H, Manias E, Lal L, et al. Impact of interventions on medication adherence and blood pressure control in patients with essential hypertension: a systematic review by the ISPOR Medication Adherence and Persistence Special Interest Group[J]. Value Health, 2013, 16(5): 863-871. DOI: 10.1016/j.jval.2013.03.1631
|
| [52] |
Martin G, Patel N, Grant Y, et al. Antihypertensive medication adherence in chronic type B aortic dissection is an important consideration in the management debate[J]. J Vasc Surg, 2018, 68(3): 693-699. e2. DOI: 10.1016/j.jvs.2017.12.063
|
| [53] |
Usai M V, Nugroho N T, Oberhuber A, et al. Influence of TEVAR on blood pressure in subacute type B aortic dissection (TBAD) patients with refractory and non-refractory arterial hypertension[J]. Int Angiol, 2021, 40(1): 60-66.
|
| [54] |
Deshpande A A, Pandey N N, Shaw M, et al. Evaluation of remodeling of visceral arteries and impact on renal function post-endovascular repair of type B aortic dissection vis-a-vis baseline visceral artery morphology[J]. Vasc Endovascular Surg, 2022, 56(6): 553-560. DOI: 10.1177/15385744221090906
|
| [55] |
Wang L C, Lin M H, Yu J J, et al. The impact of bariatric surgery versus non-surgical treatment on blood pressure: systematic review and meta-analysis[J]. Obes Surg, 2021, 31(11): 4970-4984. DOI: 10.1007/s11695-021-05671-9
|
| [56] |
Sénéchal-Dumais I, Auclair A, Leclerc J, et al. Effect of bariatric surgery on blood pressure response to exercise in a severely obese population[J]. Blood Press Monit, 2021, 26(5): 357-363. DOI: 10.1097/MBP.0000000000000543
|
| [57] |
Hawkins D N, Faler B J, Choi Y U, et al. Time course of blood pressure decrease after bariatric surgery in normoten-sive and hypertensive patients[J]. Obes Surg, 2018, 28(7): 1845-1851. DOI: 10.1007/s11695-017-3091-x
|
| [58] |
Pang K P, Pang E B, Pang K A, et al. Upper airway surgery for obstructive sleep apnea reduces blood pressure[J]. Laryngoscope, 2018, 128(2): 523-527. DOI: 10.1002/lary.26759
|
| [59] |
Lim J H, Park P, Wee J H, et al. Evaluation of the success of obstructive sleep apnea surgery using criteria based on long-term symptoms and incident hypertension[J]. Eur Arch Otorhinolaryngol, 2018, 275(4): 1015-1022. DOI: 10.1007/s00405-018-4894-7
|
| [60] |
Akinseye O A, Ralston W F, Johnson K C, et al. Renal sympathetic denervation: a comprehensive review[J]. Curr Probl Cardiol, 2021, 46(3): 100598. DOI: 10.1016/j.cpcardiol.2020.100598
|
| [61] |
Doumas M, Faselis C, Papademetriou V. Renal sympathetic denervation and systemic hypertension[J]. Am J Cardiol, 2010, 105(4): 570-576. DOI: 10.1016/j.amjcard.2009.10.027
|
| [62] |
Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study[J]. Circulation, 2011, 123(18): 1940-1946. DOI: 10.1161/CIRCULATIONAHA.110.991869
|
| [63] |
García-Touchard A, Maranillo E, Mompeo B, et al. Microdissection of the human renal nervous system: implications for performing renal denervation procedures[J]. Hypertension, 2020, 76(4): 1240-1246. DOI: 10.1161/HYPERTENSIONAHA.120.15106
|
| [64] |
Divchev D, Turan G, Rehders T, et al. Renal sympathetic denervation in patients with aortic dissection[J]. J Interv Cardiol, 2014, 27(3): 334-339. DOI: 10.1111/joic.12110
|
| [65] |
Trimarchi S, Eagle K A, Nienaber C A, et al. Importance of refractory pain and hypertension in acute type B aortic dissection: insights from the International Registry of Acute Aortic Dissection (IRAD)[J]. Circulation, 2010, 122(13): 1283-1289. DOI: 10.1161/CIRCULATIONAHA.109.929422
|
| [66] |
Ukena C, Mahfoud F, Kindermann I, et al. Cardiorespira-tory response to exercise after renal sympathetic denervation in patients with resistant hypertension[J]. J Am Coll Cardiol, 2011, 58(11): 1176-1182. DOI: 10.1016/j.jacc.2011.05.036
|
| [67] |
Lenski D, Kindermann I, Lenski M, et al. Anxiety, depression, quality of life and stress in patients with resistant hypertension before and after catheter-based renal sympathetic denervation[J]. EuroIntervention, 2013, 9(6): 700-708. DOI: 10.4244/EIJV9I6A114
|
| [68] |
Warchol-Celinska E, Prejbisz A, Kadziela J, et al. Renal denervation in resistant hypertension and obstructive sleep apnea: randomized proof-of-concept phase Ⅱ trial[J]. Hypertension, 2018, 72(2): 381-390. DOI: 10.1161/HYPERTENSIONAHA.118.11180
|
| [69] |
Ke F, Kuang W L, Hu X J, et al. A novel vaccine targeting β1-adrenergic receptor[J]. Hypertens Res, 2023, 46(6): 1582-1595. DOI: 10.1038/s41440-023-01265-3
|
| [70] |
Li C, Yan X L, Wu D Y, et al. Vaccine targeted alpha 1D-adrenergic receptor for hypertension[J]. Hypertension, 2019, 74(6): 1551-1562. DOI: 10.1161/HYPERTENSIONAHA.119.13700
|
| [71] |
Kurashiki T, Miyake T, Nakagami H, et al. Prevention of progression of aortic aneurysm by peptide vaccine against Ang Ⅱ(angiotensin Ⅱ) in a rat model[J]. Hypertension, 2020, 76(6): 1879-1888. DOI: 10.1161/HYPERTENSIONAHA.119.14442
|
| [72] |
Zhang H R, Liao M Y, Cao M S, et al. ATRQβ-001 vaccine prevents experimental abdominal aortic aneurysms[J]. J Am Heart Assoc, 2019, 8(18): e012341. DOI: 10.1161/JAHA.119.012341
|
| [73] |
Chyu K Y, Zhao X N, Zhou J C, et al. Immunization using ApoB-100 peptide-linked nanoparticles reduces atheroscler-osis[J]. JCI Insight, 2022, 7(11): e149741. DOI: 10.1172/jci.insight.149741
|
| [74] |
Natsis M, Antza C, Doundoulakis I, et al. Hypertension in obesity: novel insights[J]. Curr Hypertens Rev, 2020, 16(1): 30-36.
|
| [75] |
Wang F Z, Zhang Z, Fang A P, et al. Macrophage foam cell-targeting immunization attenuates atherosclerosis[J]. Front Immunol, 2018, 9: 3127.
|
Supported by: Beijing Renhe Information Technology Co., Ltd. 
Submit
Review
Office
Email Alert
RSS
DownLoad: